{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T02:28:47Z","timestamp":1788834527922,"version":"build-2803163510"},"reference-count":67,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T00:00:00Z","timestamp":1748563200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Latin American Psoriasis Society"},{"name":"Colombian Group of Psoriasis and Immunodermatology"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Anais Brasileiros de Dermatologia"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.abd.2025.501134","type":"journal-article","created":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T10:48:12Z","timestamp":1750243692000},"page":"501134","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Latin American consensus on tapering of biological therapy in psoriasis"],"prefix":"10.1016","volume":"100","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2209-9972","authenticated-orcid":false,"given":"Angela Mar\u00eda","family":"Londo\u00f1o-Garc\u00eda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0113-2684","authenticated-orcid":false,"given":"Juan Ra\u00fal","family":"Castro-Ayarza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2476-4991","authenticated-orcid":false,"given":"Manuel Dar\u00edo","family":"Franco Franco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5608-9054","authenticated-orcid":false,"given":"Cesar Fernando","family":"Gonz\u00e1lez Ardila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7033-2337","authenticated-orcid":false,"given":"Gabriel","family":"Magari\u00f1os","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6554-1076","authenticated-orcid":false,"given":"Enrique Salvador","family":"Rivas Zald\u00edvar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6847-3408","authenticated-orcid":false,"given":"Susan","family":"Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7191-7313","authenticated-orcid":false,"given":"Linda","family":"Ibat\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2369-3316","authenticated-orcid":false,"given":"Julieth Carolina","family":"Castillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9197-107X","authenticated-orcid":false,"given":"Paola Jimena","family":"C\u00e1rdenas Rojas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2337-2774","authenticated-orcid":false,"given":"Evelyn Giuliana","family":"Castro Vargas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1465-5126","authenticated-orcid":false,"given":"Claudia Romina","family":"Contreras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8925-0457","authenticated-orcid":false,"given":"Claudia","family":"de la Cruz Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7354-6763","authenticated-orcid":false,"given":"Andr\u00e9s","family":"Chavarriaga Restrepo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0901-5079","authenticated-orcid":false,"given":"Cristina Mariela","family":"Echeverria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0407-538X","authenticated-orcid":false,"given":"Andr\u00e9 Vicente","family":"Esteves de Carvalho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2605-0378","authenticated-orcid":false,"given":"Benjam\u00edn","family":"Hidalgo Matlock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0092-4444","authenticated-orcid":false,"given":"Enrique","family":"Loayza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-3336-0360","authenticated-orcid":false,"given":"Mat\u00edas Rafael","family":"Maskin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0165-3831","authenticated-orcid":false,"given":"Ricardo","family":"Romiti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1032-9347","authenticated-orcid":false,"given":"Fernando","family":"Valenzuela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.abd.2025.501134_bib0005","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.3390\/ijms20061475","article-title":"Psoriasis pathogenesis and treatment","volume":"20","author":"Rendon","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.abd.2025.501134_bib0010","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1111\/jdv.14393","article-title":"Psoriasis in Latin America and the Caribbean: a systematic review","volume":"31","author":"Hern\u00e1ndez-V\u00e1squez","year":"2017","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"10.1016\/j.abd.2025.501134_bib0015","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1111\/bjd.19039","article-title":"British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020: a rapid update","volume":"183","author":"Smith","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.abd.2025.501134_bib0020","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s40265-020-01448-z","article-title":"Dose tapering of biologics in patients with psoriasis: a scoping review","volume":"81","author":"Michielsens","year":"2021","journal-title":"Drugs."},{"key":"10.1016\/j.abd.2025.501134_bib0025","series-title":"Cost of diagnosis and treatment of plaque psoriasis in the Colombian population over 18 years of age, from the perspective of the General System of Social Security in Health","author":"Ca\u00f1\u00f3n Betancourt","year":"2022"},{"key":"10.1016\/j.abd.2025.501134_bib0030","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.ad.2016.04.018","article-title":"The cost of psoriasis and psoriatic arthritis in 5 european countries: a systematic review","volume":"107","author":"Burgos-Pol","year":"2016","journal-title":"Actas Dermo-Sifiliogr\u00e1ficas."},{"key":"10.1016\/j.abd.2025.501134_bib0035","series-title":"Cochrane handbook for systematic reviews of interventions version 6.0 (updated July 2019)","author":"Higgins","year":"2019"},{"key":"10.1016\/j.abd.2025.501134_bib0040","series-title":"The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses","author":"Wells","year":"2000"},{"key":"10.1016\/j.abd.2025.501134_bib0045","series-title":"In: JBI Manual for Evidence Synthesis","article-title":"Chapter 7: systematic reviews of etiology and risk","author":"Moola","year":"2020"},{"key":"10.1016\/j.abd.2025.501134_bib0050","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/1471-2288-7-52","article-title":"An exploration of the use of simple statistics to measure consensus and stability in Delphi studies","volume":"7","author":"Holey","year":"2007","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.abd.2025.501134_bib0055","doi-asserted-by":"crossref","DOI":"10.2340\/00015555-3815","article-title":"Evaluation of a one-step dose reduction strategy of adalimumab, etanercept and ustekinumab in patients with psoriasis in daily practice","volume":"101","author":"Atalay","year":"2021","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.abd.2025.501134_bib0060","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1111\/bjd.15656","article-title":"Secukinumab re-initiation achieves regain of high response levels in patients who interrupt treatment for moderate to severe plaque psoriasis","volume":"177","author":"Blauvelt","year":"2017","journal-title":"Br J Dermatol."},{"key":"10.1016\/j.abd.2025.501134_bib0065","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1111\/bjd.18484","article-title":"Efficacy and safety of tildrakizumab for plaque psoriasis with continuous dosing, treatment interruption, dose adjustments and switching from etanercept: results from phase III studies.","volume":"182","author":"Kimball","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.abd.2025.501134_bib0070","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1056\/NEJMoa1503824","article-title":"Phase 3 studies comparing brodalumab with ustekinumab in psoriasis","volume":"373","author":"Lebwohl","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.abd.2025.501134_bib0075","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1111\/bjd.18143","article-title":"Secukinumab dosing optimization in patients with moderate-to-severe plaque psoriasis: results from the randomized, open-label OPTIMISE study","volume":"182","author":"Reich","year":"2020","journal-title":"Br J Dermatol."},{"key":"10.1016\/j.abd.2025.501134_bib0080","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/j.1365-2133.2010.10139.x","article-title":"Adalimumab for moderate to severe chronic plaque psoriasis: efficacy and safety of retreatment and disease recurrence following withdrawal from therapy","volume":"164","author":"Papp","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.abd.2025.501134_bib0085","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1177\/247553031117a00201","article-title":"Efficacy and safety of a second adalimumab treatment cycle in psoriasis patients who relapsed after adalimumab discontinuation or dosage reduction: a double-blind, randomized, placebo-controlled trial.","volume":"17a","author":"Larian","year":"2011","journal-title":"Psoriasis Forum."},{"key":"10.1016\/j.abd.2025.501134_bib0090","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1111\/j.1365-2133.2005.06688.x","article-title":"A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction","volume":"152","author":"Papp","year":"2005","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.abd.2025.501134_bib0095","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1111\/jdv.12677","article-title":"Adalimumab retreatment successfully restores clinical response and health-related quality of life in patients with moderate to severe psoriasis who undergo therapy interruption","volume":"29","author":"Gordon","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.abd.2025.501134_bib0100","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1111\/j.1365-2133.2009.09238.x","article-title":"Patients with moderate-to-severe psoriasis recapture clinical response during re-treatment with etanercept","volume":"161","author":"Ortonne","year":"2009","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.abd.2025.501134_bib0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/jamadermatol.2020.0723","article-title":"Efficacy and safety of continuous risankizumab therapy vs treatment withdrawal in patients with moderate to severe plaque psoriasis","volume":"156","author":"Blauvelt","year":"2020","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.abd.2025.501134_bib0110","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1080\/09546630500472838","article-title":"Clinical response in psoriasis patients discontinued from and then reinitiated on etanercept therapy.","volume":"17","author":"Gordon","year":"2006","journal-title":"J Dermatol Treat."},{"key":"10.1016\/j.abd.2025.501134_bib0115","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1586\/17469872.3.6.657","article-title":"Efficacy and safety of continuous versus paused etanercept treatment in patients with moderate-to-severe psoriasis over 54 weeks: the CRYSTEL study","volume":"3","author":"Ortonne","year":"2008","journal-title":"Expert Rev Dermatol."},{"key":"10.1016\/j.abd.2025.501134_bib0120","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jaad.2007.09.010","article-title":"Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial","volume":"58","author":"Menter","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.abd.2025.501134_bib0125","doi-asserted-by":"crossref","DOI":"10.1111\/dth.15911","article-title":"Gradually increasing the dosing interval of Secukinumab for moderate to severe plaque psoriasis: a single-center, uncontrolled, prospective study in 36 weeks","volume":"35","author":"Chen","year":"2022","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.abd.2025.501134_bib0130","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.ad.2015.02.003","article-title":"Dose modification in biologic therapy for moderate to severe psoriasis: a descriptive analysis in a clinical practice setting","volume":"106","author":"Baniandr\u00e9s","year":"2015","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.abd.2025.501134_bib0135","first-page":"1584","article-title":"Down-titration of infliximab: the real-life use in psoriatic patients","volume":"15","author":"Bardazzi","year":"2016","journal-title":"J Drugs Dermatol."},{"key":"10.1016\/j.abd.2025.501134_bib0140","doi-asserted-by":"crossref","first-page":"502","DOI":"10.3109\/09546634.2015.1034070","article-title":"Use of off-label doses is frequent in biologic therapy for moderate to severe psoriasis: a cross-sectional study in clinical practice","volume":"26","author":"Carrascosa","year":"2015","journal-title":"J Dermatol Treat."},{"key":"10.1016\/j.abd.2025.501134_bib0145","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1111\/jdv.14145","article-title":"Dose adjustment of biologic therapies for psoriasis in dermatological practice: a retrospective study","volume":"31","author":"Esposito","year":"2017","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"10.1016\/j.abd.2025.501134_bib0150","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1111\/j.1468-3083.2011.04290.x","article-title":"Adalimumab for psoriasis in Greece: clinical experience in a tertiary referral centre","volume":"26","author":"Fotiadou","year":"2012","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"10.1016\/j.abd.2025.501134_bib0155","doi-asserted-by":"crossref","first-page":"346","DOI":"10.2340\/00015555-2571","article-title":"Adalimumab dose tapering in psoriasis: predictive factors for maintenance of complete clearance","volume":"97","author":"Hansel","year":"2017","journal-title":"Acta Derm Venereol."},{"key":"10.1016\/j.abd.2025.501134_bib0160","doi-asserted-by":"crossref","first-page":"e292","DOI":"10.1111\/jdv.14826","article-title":"Dosage adjustments in patients with psoriasis on adalimumab - a retrospective chart review","volume":"32","author":"Lee","year":"2018","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"10.1016\/j.abd.2025.501134_bib0165","doi-asserted-by":"crossref","DOI":"10.1111\/dth.14134","article-title":"Reduced doses of biological therapies in psoriasis may increase efficiency without decreasing drug survival","volume":"33","author":"Llamas-Velasco","year":"2020","journal-title":"Dermatol Ther."},{"key":"10.1016\/j.abd.2025.501134_bib0170","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1111\/bjd.12543","article-title":"Adalimumab for the treatment of psoriasis in real life: a retrospective cohort of 119 patients at a single Spanish centre","volume":"169","author":"L\u00f3pez-Ferrer","year":"2013","journal-title":"Br J Dermatol."},{"key":"10.1016\/j.abd.2025.501134_bib0175","doi-asserted-by":"crossref","first-page":"e271","DOI":"10.1111\/jdv.16256","article-title":"Polymorphisms associated with optimization of biological therapy through drug dose reduction in moderate-to-severe psoriasis","volume":"34","author":"Ovejero-Benito","year":"2020","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"10.1016\/j.abd.2025.501134_bib0180","doi-asserted-by":"crossref","first-page":"251","DOI":"10.2340\/00015555-2209","article-title":"Down-titration of adalimumab and etanercept in psoriatic patients: a multicentre observational study","volume":"96","author":"Piaserico","year":"2016","journal-title":"Acta Der. Venereol."},{"key":"10.1016\/j.abd.2025.501134_bib0185","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1684\/ejd.2013.2017","article-title":"Implementing therapeutic goals in maintenance treatment of psoriasis with biologics: adalimumab can be more cost-effective than infliximab or ustekinumab in real life","volume":"23","author":"Puig","year":"2013","journal-title":"Eur J Dermatol."},{"key":"10.1016\/j.abd.2025.501134_bib0190","doi-asserted-by":"crossref","first-page":"198","DOI":"10.3109\/09546634.2015.1088127","article-title":"Efficiency of biological therapies in patients with moderate to severe psoriasis: impact of a pharmacotherapeutic protocol","volume":"27","author":"Romero-Jimenez","year":"2016","journal-title":"J Dermatol Treat."},{"key":"10.1016\/j.abd.2025.501134_bib0195","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1080\/09546634.2018.1466978","article-title":"Association between clinical factors and dose modification strategies in the treatment with ustekinumab for moderate-to-severe plaque psoriasis","volume":"29","author":"Romero-Jimenez","year":"2018","journal-title":"J Dermatol Treat."},{"key":"10.1016\/j.abd.2025.501134_bib0200","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1111\/j.1468-3083.2012.04610.x","article-title":"An observational, prospective study of monthly adalimumab therapy for disease maintenance in psoriasis patients: a possible new therapeutic option for good responders to the initial induction treatment","volume":"27","author":"Taniguchi","year":"2013","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"10.1016\/j.abd.2025.501134_bib0205","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1097\/FTD.0000000000000420","article-title":"Prolongation of biologic dosing intervals in patients with stable psoriasis: a feasibility study","volume":"39","author":"van Bezooijen","year":"2017","journal-title":"Ther Drug Monit."},{"key":"10.1016\/j.abd.2025.501134_bib0210","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1177\/039463201002300314","article-title":"Treatment of psoriasis with different dosage regimens of etanercept: preliminary results from the T\u03b1ranta Plastic Study Group","volume":"23","author":"Cassano","year":"2010","journal-title":"Int J Immunopathol Pharmacol."},{"key":"10.1016\/j.abd.2025.501134_bib0215","first-page":"S65","article-title":"Biological therapy optimization in patients with psoriasis by reducing the dose or increasing the time interval, in a specialized centre in Colombia","volume":"30","author":"Castro-Ayarza","year":"2023","journal-title":"Rev Colomb Reumatol."},{"key":"10.1016\/j.abd.2025.501134_bib0220","first-page":"166","article-title":"Is it possible to optimize biologic therapy in patients with psoriasis? Rev Colom","volume":"31","author":"Londo\u00f1o-Garc\u00eda","year":"2022","journal-title":"Reumatol."},{"key":"10.1016\/j.abd.2025.501134_bib0225","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1016\/j.jaad.2021.04.093","article-title":"Extended dosing intervals of ixekizumab for psoriasis: a single-center, uncontrolled, prospective study","volume":"86","author":"Ye","year":"2022","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.abd.2025.501134_bib0230","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1080\/09546634.2017.1395794","article-title":"Redefining the therapeutic objective in psoriatic patients candidates for biological therapy","volume":"29","author":"Carretero","year":"2018","journal-title":"J Dermatol Treat."},{"issue":"Suppl 2","key":"10.1016\/j.abd.2025.501134_bib0235","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/jdv.13542","article-title":"Consensus document on the evaluation and treatment of moderate-to-severe psoriasis: Psoriasis Group of the Spanish Academy of Dermatology and Venereology","volume":"30","author":"Daud\u00e9n","year":"2016","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"10.1016\/j.abd.2025.501134_bib0240","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.ad.2016.04.017","article-title":"Expert recommendations on treating psoriasis in special circumstances (Part II)","volume":"107","author":"Carrascosa","year":"2016","journal-title":"Actas Dermosifiliogr."},{"key":"10.1016\/j.abd.2025.501134_bib0245","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/jdv.15340","article-title":"French guidelines on the use of systemic treatments for moderate-to-severe psoriasis in adults","volume":"33","author":"Amatore","year":"2019","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"10.1016\/j.abd.2025.501134_bib0250","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/1346-8138.15196","article-title":"Japanese guidance for use of biologics for psoriasis (the 2019 version)","volume":"47","author":"Saeki","year":"2020","journal-title":"J Dermatol"},{"key":"10.1016\/j.abd.2025.501134_bib0255","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s00403-021-02273-4","article-title":"Attitudes and behaviour regarding dose reduction of biologics for psoriasis: a survey among dermatologists worldwide","volume":"314","author":"van Muijen","year":"2022","journal-title":"Arch Dermatol Res."},{"key":"10.1016\/j.abd.2025.501134_bib0260","series-title":"16-week treatment interval of guselkumab is non-inferior to 8-week dosing for maintaining psoriasis control in super responders: GUIDE study primary result. Abstract n\u00ba 3465","first-page":"7","author":"Sch\u00e4kel","year":"2022"},{"key":"10.1016\/j.abd.2025.501134_bib0265","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1080\/09546634.2020.1869147","article-title":"Two-year follow-up of a dose reduction strategy trial of biologics adalimumab, etanercept, and ustekinumab in psoriasis patients in daily practice","volume":"33","author":"Atalay","year":"2021","journal-title":"J Dermatol Treat."},{"key":"10.1016\/j.abd.2025.501134_bib0270","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1111\/bjd.15722","article-title":"Extension of ustekinumab maintenance dosing interval in moderate-to-severe psoriasis: results of a phase IIIb, randomized, double-blinded, active-controlled, multicentre study (PSTELLAR)","volume":"177","author":"Blauvelt","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.abd.2025.501134_bib0275","first-page":"11","article-title":"Efficacy and safety of adalimumab treatment in patients with moderate to severe psoriasis: a double-blind, randomized clinical trial","volume":"13a","author":"Gordon","year":"2007","journal-title":"J Psoriasis Psoriatic Arthritis."},{"key":"10.1016\/j.abd.2025.501134_bib0280","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.jaad.2006.09.002","article-title":"A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis","volume":"56","author":"Moore","year":"2007","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.abd.2025.501134_bib0285","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.jaad.2016.11.042","volume":"76","author":"Reich","year":"2017","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.abd.2025.501134_bib0290","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/jdv.15292","article-title":"Long-term efficacy and safety results from an open-label phase III study (UNCOVER-J) in Japanese plaque psoriasis patients: impact of treatment withdrawal and retreatment of ixekizumab","volume":"33","author":"Umezawa","year":"2019","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"10.1016\/j.abd.2025.501134_bib0295","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/jdv.16803","article-title":"Intermittent use of biologic agents for the treatment of psoriasis in adults","volume":"35","author":"Al-Hammadi","year":"2021","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"10.1016\/j.abd.2025.501134_bib0300","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/j.1365-2133.2012.10941.x","article-title":"Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab\u2019 certolizumab pegol: results of a phase II randomized, placebo-controlled trial with a re-treatment extension","volume":"167","author":"Reich","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.abd.2025.501134_bib0305","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1111\/jdv.13673","article-title":"An observational study to evaluate the long-term outcomes of treatment with etanercept in patients with plaque-type psoriasis","volume":"30","author":"Luger","year":"2016","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"10.1016\/j.abd.2025.501134_bib0310","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1111\/jdv.12585","article-title":"Retreatment in patients with psoriasis achieving response with etanercept after relapse due to treatment interruption: results from the CRYSTEL study","volume":"29","author":"Griffiths","year":"2015","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"10.1016\/j.abd.2025.501134_bib0315","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1111\/bjd.12404","article-title":"Efficacy and safety of infliximab as continuous or intermittent therapy in patients with moderate-to-severe plaque psoriasis: results of a randomized, long-term extension trial (RESTORE2)","volume":"168","author":"Reich","year":"2013","journal-title":"Br J Dermatol."},{"key":"10.1016\/j.abd.2025.501134_bib0320","doi-asserted-by":"crossref","first-page":"179","DOI":"10.5021\/ad.2018.30.2.179","article-title":"Economic burden can be the major determining factor resulting in short-term intermittent and repetitive ustekinumab treatment for moderate-to-severe psoriasis","volume":"30","author":"Choi","year":"2018","journal-title":"Ann Dermatol."},{"key":"10.1016\/j.abd.2025.501134_bib0325","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/S0140-6736(08)60725-4","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)","volume":"371","author":"Leonardi","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.abd.2025.501134_bib0330","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/bjd.14493","article-title":"A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis","volume":"175","author":"Papp","year":"2016","journal-title":"Br J Dermatol."},{"key":"10.1016\/j.abd.2025.501134_bib0335","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1001\/jamadermatol.2019.4897","article-title":"Comparison of tightly controlled dose reduction of biologics with usual care for patients with psoriasis: a randomized clinical trial","volume":"156","author":"Atalay","year":"2020","journal-title":"JAMA Dermatol."}],"container-title":["Anais Brasileiros de Dermatologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0365059625000765?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0365059625000765?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:09:06Z","timestamp":1762301346000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0365059625000765"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":67,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S0365059625000765"],"URL":"https:\/\/doi.org\/10.1016\/j.abd.2025.501134","relation":{},"ISSN":["0365-0596"],"issn-type":[{"value":"0365-0596","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Latin American consensus on tapering of biological therapy in psoriasis","name":"articletitle","label":"Article Title"},{"value":"Anais Brasileiros de Dermatologia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.abd.2025.501134","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Sociedade Brasileira de Dermatologia. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}],"article-number":"501134"}}